23andMe to Report Q1 FY2025 Financial Results
23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has announced it will report its Q1 FY2025 financial results on Thursday, August 8, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the quarter's results and business progress.
Shareholders can access the webcast at https://investors.23andme.com/news-events/events-presentations. Additionally, 23andMe is using the Say Technologies platform to allow shareholders to submit and upvote questions for management before the earnings call. The Q&A platform will be open until 24 business hours before the call.
23andMe Holding Co. (Nasdaq: ME), un'azienda leader nel settore della genetica umana e della biofarmaceutica, ha annunciato che riporterà i propri risultati finanziari del Q1 FY2025 giovedì, 8 agosto 2024, al termine della giornata di mercato. L'azienda ospiterà una conference call e un webcast alle 16:30 ora orientale per discutere i risultati del trimestre e i progressi aziendali.
Gli azionisti possono accedere al webcast su https://investors.23andme.com/news-events/events-presentations. Inoltre, 23andMe utilizza la piattaforma Say Technologies per consentire agli azionisti di inviare e votare domande per la direzione prima della chiamata sugli utili. La piattaforma Q&A sarà aperta fino a 24 ore lavorative prima della chiamata.
23andMe Holding Co. (Nasdaq: ME), una empresa líder en genética humana y biofarmacéutica, ha anunciado que informará sobre sus resultados financieros del Q1 FY2025 el jueves, 8 de agosto de 2024, después del cierre del mercado. La empresa realizará una llamada de conferencia y un webcast a las 4:30 p.m. hora del este para discutir los resultados del trimestre y el progreso del negocio.
Los accionistas pueden acceder al webcast en https://investors.23andme.com/news-events/events-presentations. Además, 23andMe está utilizando la plataforma Say Technologies para permitir a los accionistas enviar y votar preguntas para la dirección antes de la llamada de ganancias. La plataforma de preguntas y respuestas estará abierta hasta 24 horas hábiles antes de la llamada.
23andMe Holding Co. (Nasdaq: ME), 선도적인 인간 유전자 및 생명공학 회사,는 2025 회계 연도 1분기 재무 결과를 2024년 8월 8일 목요일, 시장 종료 후에 발표할 예정이라고 발표했습니다. 회사는 동부 표준시 오후 4시 30분에 분기 결과 및 비즈니스 진행 상황을 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 주최합니다.
주주는 https://investors.23andme.com/news-events/events-presentations에서 웹캐스트에 접속할 수 있습니다. 또한, 23andMe는 Say Technologies 플랫폼을 사용하여 주주들이 실적 발표 전 경영진에게 질문을 제출하고 투표할 수 있도록 하고 있습니다. Q&A 플랫폼은 통화 24시간 전까지 열려 있습니다.
23andMe Holding Co. (Nasdaq: ME), une entreprise leader en génétique humaine et en bio-pharmaceutique, a annoncé qu'elle publiera ses résultats financiers du Q1 FY2025 le jeudi 8 août 2024, après la fermeture du marché. L'entreprise organisera une conférence téléphonique et un webcast à 16h30 heure de l'Est pour discuter des résultats du trimestre et des avancées de l'entreprise.
Les actionnaires peuvent accéder au webcast sur https://investors.23andme.com/news-events/events-presentations. De plus, 23andMe utilise la plateforme Say Technologies pour permettre aux actionnaires de soumettre et de voter pour des questions destinées à la direction avant l'appel de résultats. La plateforme de questions-réponses sera ouverte jusqu'à 24 heures ouvrables avant l'appel.
23andMe Holding Co. (Nasdaq: ME), ein führendes Unternehmen in der menschlichen Genetik und Biopharmazeutik, hat angekündigt, dass die Finanzergebnisse für Q1 FY2025 am Donnerstag, den 8. August 2024, nach Handelsende veröffentlicht werden. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast abhalten, um die Ergebnisse des Quartals und den Fortschritt des Unternehmens zu besprechen.
Aktionäre können den Webcast unter https://investors.23andme.com/news-events/events-presentations abrufen. Darüber hinaus nutzt 23andMe die Plattform Say Technologies, um den Aktionären zu ermöglichen, Fragen an das Management vor dem Gewinnaufruf einzureichen und zu bewerten. Die Q&A-Plattform wird bis 24 Geschäftsstunden vor dem Anruf geöffnet sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the first quarter of fiscal year 2025 (FY2025) after the market closes on Thursday, August 8, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s results and report on business progress.
The webcast can be accessed on the day of the event at https://investors.23andme.com/news-events/events-presentations. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional shareholders to submit and upvote questions to management in advance of the earnings conference call. Starting today, shareholders can submit questions by visiting https://app.saytechnologies.com/23andme-2025-q1. The Q&A platform will remain open until 24 business hours before the earnings call.
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit investors.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the future performance of 23andMe’s businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding 23andMe’s strategy, financial position, financial projections, funding for continued operations, cash reserves, projected costs, database growth, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
Contacts
Investor Relations Contact: Ian Cooney, ianc@23andme.com
Media Contact: press@23andMe.com
FAQ
When will 23andMe (ME) report its Q1 FY2025 financial results?
How can I listen to 23andMe's (ME) Q1 FY2025 earnings conference call?
How can shareholders submit questions for 23andMe's (ME) Q1 FY2025 earnings call?
What is the Nasdaq stock symbol for 23andMe?
